Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II/III trial of doxycycline vs standard supportive therapy in newly diagnosed cardiac AL amyloidosis
2017-002210-31Phase 2Terminated
- Sponsor
- Amyloid Solutions
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of doxycycline in light-chain amyloidosis (2 arms), sponsored by Amyloid Solutions. Primary endpoint: 12-month survival proportion. Started Jan 2019; status: terminated.
02
Drugs
doxycycline
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2017-002210-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002210-31.